7 min read

Gujarat Alkalies' Margin Rose Four Points in a Year. The Company Credits Prices, and the Power Bill Still Rose

Gujarat Alkalies' Q2 FY27 EBITDA margin rose to 15.74% from 11.6%. The company credits prices and mix; power spend still rose faster than sales.

The idea in one sentence

Gujarat Alkalies and Chemicals (GACL) earned a standalone EBITDA margin of 15.74% on total income in the September 2026 quarter, up from 11.6% a year earlier, and the company credits better selling prices and a better product mix for it, while the cheaper power the company is building shows up in the rate per unit but not yet in the total power bill [T][R].

The quarter and the half year

All numbers here are standalone, from the 5 November results [R], unless marked otherwise. The 17 November filing is the transcript of the 12 November earnings call [T].

  • Revenue from operations, Q2 FY27: ₹1,357.50 crore, against ₹1,083.19 crore a year earlier, up 25.3% (our arithmetic) [R].
  • EBITDA: ₹221.86 crore against ₹133.19 crore [PR].
  • Profit before tax: ₹102.10 crore against ₹13.48 crore [PR][R].
  • Profit after tax: ₹79.24 crore against ₹16.28 crore, about 4.9 times (our arithmetic) [R].
  • First half: revenue from operations ₹2,602.41 crore against ₹2,188.31 crore; profit before tax ₹212.14 crore against ₹23.03 crore; profit after tax ₹132.64 crore against ₹24.07 crore [R].

The managing director put the margin this way on the call: "Our EBITDA margin on total income improved to 15.74% compared with 11.6% in Q2 of the previous year." For the half year the call gives 16.95% against 11.45% [T].

One caution on the quarter. EBITDA includes other income, which was ₹51.94 crore in Q2 against ₹59.29 crore a year ago [R]. Take it out and EBITDA was about ₹169.92 crore, or 12.5% of revenue from operations, against about ₹73.90 crore, or 6.8% (our arithmetic). The operating improvement is real, about 5.7 points on that measure (our arithmetic), but the headline margin flatters it a little.

What the company says caused it

The call's opening remarks give the cause directly: "The improvement in Q2 was primarily supported by better realizations and a more favorable product and market mix." Domestic sales rose 29% and exports 14% [T]. The press note adds that better sales realisations came from "product mix optimization, increased share of renewable energy and expanding product footprint through new export markets" [PR].

Management named the price moves. On the call, the chlorotoluene group commanded "almost 100%" more than a year earlier, phosphoric acid about 44%, hydrogen peroxide 31% (worded on the call as "over the previous quarter"), and the caustic soda group about 10% [T]. The answer is loosely worded (it mixes "same quarter" and "previous quarter"), so read these as management's indication, not a measured series.

Chlorine, the by-product of making caustic soda, also helped. Management said: "The chlorine prices has been substantially negative, which has improved significantly during the quarter to maintain the ECU levels." No chlorine or ECU figure is filed [T].

Segments

There is no segment table to dissect. Note 4 of [R] says "The Company's operations fall under single segment namely "Chemicals" as per Ind AS -108 "Segment Reporting"". So the filings cannot show whether caustic soda or the chlorine and value-added products earned the margin. On the call, an analyst said value-added products apart from caustic soda were "close to around 61% of sales" in Q2, and management declined to split EBITDA by product [T].

Power: the rate fell, the bill did not

This is where the "cost advantage" question gets tested. Power, fuel and other utilities were ₹421.81 crore in Q2, against ₹306.70 crore a year earlier, up 37.5% (our arithmetic), while revenue from operations rose 25.3% [R]. As a share of revenue it went from 28.3% to 31.1% (our arithmetic). Against the previous quarter, the line rose from ₹370.98 crore, and the share from 29.8% (our arithmetic).

So power spend absorbed margin, not added to it. What did improve is the price paid per unit and the mix:

  • Renewable energy was "approximately 55% of our power consumption in Q2, compared with 38%" a year ago, and about 57% for the first half against 38% [T].
  • "The average H1 power rate reduced to INR7.09 per unit from INR7.6 per unit in the corresponding period." That is a fall of about 6.7% (our arithmetic) [T].
  • Management said the reduction was held back because of "rise in the DISCOM power rates by about INR0.45" and "a delay in commissioning of our long-term RE of ABRen", which it covered by buying short-term renewable power [T].

The H1 power mix, as given on the call, matters for durability: grid power plus the GNAL joint venture's captive power was 43%, short-term renewable 28% (about 52 MW), and the company's own wind assets 29% (about 53 MW) [T]. Our reading: only about the 29% is owned capacity. The 28% bought short-term is a market purchase, so it lowers the rate but is not yet a lock-in.

The targets are stated: renewable share to 60% by March 2027 with power cost "likely to reduce to INR6.18 per kWH", and by FY30 "to increase the share of RE to 80% and reduce the power cost to less than INR6" [T].

Volumes, capacity and chlorine

Product-wise sales volumes are not given; management offered to share them separately. On utilisation, management put the average at "about 92%", "slightly marginally lower as compared to previous year" because of grid disturbances and shutdowns, with the chlorotoluene plant at about 90% [T]. On exports, management said caustic soda goes out at about 5 KT a month in liquid form (around 60,000 tons a year) and 10,000 to 12,000 tons a month in solid form [T]. The company describes caustic soda capacity of 8,52,400 TPA across four complexes [PR].

Chlorine integration, meaning how much chlorine is used inside the company's own products, was "close to about 45%", with a target of "almost 75%" in two to three years as the HCl synthesis and other units come on [T]. A caustic plant has to sell its chlorine; the more it uses itself, the less it depends on the chlorine market.

What management said about the outlook

  • On current prices: "Current market realizations are better than Q2, especially if you are talking about the caustic soda. However, the energy cost impacts are there." No number was given [T].
  • On the long-term aspiration: "becoming a INR10,000 crores plus revenue company with EBITDA margins above 20% by FY 2031. This remains a medium-term aspiration rather than near-term financial guidance" [T].
  • On the cycle: "We remain mindful that chemical businesses are cyclical" [T].
  • On funding growth: "the funding will be from a mix of internal accruals as well as borrowings" [T]. Annualised return on capital employed for H1 was about 8.52%, against 1.87% for FY26 [T].

Recap

One idea, three facts. Margin rose about four points on total income. The company attributes it to prices and mix. Power spend rose faster than sales, though the rate per unit fell. The filings do not split the gain between price and cost, so neither the share from prices nor the share from cost can be stated.

Verdicts

Moat verdict (cost advantage, D3). Not yet shown in the numbers. The direction is right: renewable share up from 38% to 55%, the per-unit rate down to ₹7.09 from ₹7.6 in the half year, and a stated path to under ₹6. But in Q2 power cost took a larger share of revenue than a year ago, more than a quarter of the power mix is short-term purchase, and the filings give no cost per tonne. The scale (8,52,400 TPA of caustic soda capacity) is stated, but a scale advantage needs a cost figure the filings do not give. We leave it unscored: GACL is not on the Moat Screener.

Margin verdict. Real but price-led. The margin gain sits alongside realisation increases in a business that management itself calls cyclical, and the sequential margin slipped: Q1 FY27 EBITDA on total income was about 18.3% against 15.74% in Q2 (our arithmetic, from [R]). Durability depends on whether the realisations hold and whether renewable supply arrives on time.

Bear case

  • Price can reverse. The gain is credited to "better realizations"; management says chemical businesses are cyclical, and "large capacities" of caustic soda are coming from others, which management answered with cost and market focus, not a number [T].
  • Power bill grew faster than sales. ₹421.81 crore against ₹306.70 crore, up 37.5% (our arithmetic) [R].
  • Quarter on quarter, profit before tax fell. Standalone profit before tax was ₹102.10 crore in Q2 against ₹110.04 crore in Q1, and management cited a low wind period and power cost [R][T].
  • Other income is large. ₹51.94 crore in Q2, about half of profit before tax (our arithmetic) [R].
  • Delay risk. The long-term renewable supply from ABRen was late; the 70%-plus renewable ambition rests on projects still under way [T].
  • Funding is open. Growth capex is to come from internal accruals and borrowings, with no figure given for either [T].

What to watch

  • Standalone power, fuel and utilities as a share of revenue in Q3 FY27, against 31.1% in Q2 (our arithmetic).
  • The renewable share against the stated 60% by March 2027, and the power rate against ₹6.18 per unit.
  • Whether "current market realizations" stay above Q2 levels, and whether chlorine realisations stay positive.
  • The December 2026 target for the 200 TPD caustic soda flaking unit and the January 2027 target for the 120 TPD HCl synthesis unit [T].
  • Chlorine integration against the 45% now and 75% target.
  • Any filing that gives product-wise volumes, borrowings, or a capex figure for the FY31 aspiration.

Sources


Educational research, not investment advice. Every figure above is drawn from Gujarat Alkalies and Chemicals Limited's own filings (the results and limited review reports and press note of 5 November 2026, and the earnings-call transcript filed on 17 November 2026), read from the primary documents on 18 November 2026; derived figures are our arithmetic, labelled as such. MoatSCORE: not yet scored (Gujarat Alkalies is not listed on the Moat Screener, checked 18 Nov 2026). No buy/sell recommendations, no price targets, no share prices. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.